AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
Log in

NASDAQ:TWSTTwist Bioscience Stock Price, Forecast & News

$40.00
+2.05 (+5.40 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$37.22
Now: $40.00
$40.15
50-Day Range
$26.51
MA: $34.42
$41.46
52-Week Range
$18.52
Now: $40.00
$42.17
Volume653,340 shs
Average Volume554,509 shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.21
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.13 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TWST
CUSIPN/A
CIKN/A
Phone800-719-0671

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.38 million
Book Value$4.63 per share

Profitability

Net Income$-107,670,000.00
Net Margins-222.66%

Miscellaneous

Employees289
Market Cap$1.64 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

How has Twist Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TWST shares have increased by 41.8% and is now trading at $40.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Twist Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Twist Bioscience.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Twist Bioscience.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Corp (NASDAQ:TWST) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.85) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.75) by $0.10. The business had revenue of $19.30 million for the quarter, compared to analysts' expectations of $17.18 million. Twist Bioscience had a negative return on equity of 71.31% and a negative net margin of 222.66%. The company's quarterly revenue was up 41.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.93) EPS. View Twist Bioscience's earnings history.

What price target have analysts set for TWST?

2 brokerages have issued 1-year price objectives for Twist Bioscience's shares. Their forecasts range from $42.00 to $42.00. On average, they expect Twist Bioscience's share price to reach $42.00 in the next year. This suggests a possible upside of 5.0% from the stock's current price. View analysts' price targets for Twist Bioscience.

Has Twist Bioscience been receiving favorable news coverage?

News headlines about TWST stock have been trending extremely negative recently, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Twist Bioscience earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutTwist Bioscience.

Are investors shorting Twist Bioscience?

Twist Bioscience saw a increase in short interest in April. As of April 30th, there was short interest totaling 4,400,000 shares, an increase of 5.0% from the April 15th total of 4,190,000 shares. Based on an average daily trading volume, of 611,600 shares, the days-to-cover ratio is currently 7.2 days. Approximately 16.5% of the shares of the stock are sold short. View Twist Bioscience's Current Options Chain.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include Canopy Growth (CGC), Gilead Sciences (GILD), Square (SQ), AbbVie (ABBV), Aurora Cannabis (ACB), Amarin (AMRN), Arcturus Therapeutics (ARCT), Alibaba Group (BABA), Inovio Pharmaceuticals (INO) and Iovance Biotherapeutics (IOVA).

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 64)
  • Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Gen. Counsel, Chief Ethics & Compliance Officer and Sec. (Age 56)
  • Mr. William Charles Banyai, COO & Director (Age 64)
  • Mr. Bill Peck, Chief Technology Officer (Age 59)

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (7.62%), BlackRock Inc. (6.85%), Wellington Management Group LLP (3.75%), Casdin Capital LLC (2.82%), State Street Corp (2.71%) and Bank of New York Mellon Corp (2.60%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View institutional ownership trends for Twist Bioscience.

Which major investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Squarepoint Ops LLC, Federated Hermes Inc., Wells Fargo & Company MN, Morgan Stanley, Deutsche Bank AG, UBS Group AG, and Windsor Creek Advisors LLC. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, Emily M Leproust, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, and William Banyai. View insider buying and selling activity for Twist Bioscience.

Which major investors are buying Twist Bioscience stock?

TWST stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bank of New York Mellon Corp, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Casdin Capital LLC, William Blair Investment Management LLC, and Redmile Group LLC. View insider buying and selling activity for Twist Bioscience.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $40.00.

How big of a company is Twist Bioscience?

Twist Bioscience has a market capitalization of $1.64 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.